🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 23/03/2016 | 86,00 | 86,00 | 80,00 | 80,15 | -7,64% | 6,98% | 2.198.100 |
| 22/03/2016 | 83,65 | 86,91 | 83,31 | 86,78 | +3,28% | 4,30% | 1.785.200 |
| 21/03/2016 | 82,01 | 84,75 | 81,52 | 84,02 | +1,82% | 3,94% | 1.784.000 |
| 18/03/2016 | 79,74 | 83,14 | 78,47 | 82,52 | +4,22% | 5,86% | 3.768.300 |
| 17/03/2016 | 79,33 | 80,09 | 75,90 | 79,18 | -0,15% | 5,28% | 2.658.000 |
| 16/03/2016 | 82,06 | 83,34 | 77,51 | 79,30 | -4,26% | 7,10% | 2.957.300 |
| 15/03/2016 | 84,55 | 85,41 | 82,25 | 82,83 | -3,22% | 3,74% | 1.762.600 |
| 14/03/2016 | 86,11 | 86,96 | 83,98 | 85,59 | -0,78% | 3,46% | 2.014.300 |
| 11/03/2016 | 83,82 | 86,34 | 83,03 | 86,26 | +4,84% | 3,95% | 1.715.900 |
| 10/03/2016 | 85,16 | 85,43 | 81,16 | 82,28 | -2,78% | 5,01% | 2.456.600 |
| 09/03/2016 | 87,45 | 87,45 | 84,35 | 84,63 | -2,62% | 3,54% | 2.201.800 |
| 08/03/2016 | 90,63 | 90,89 | 85,05 | 86,91 | -4,44% | 6,44% | 2.776.500 |
| 07/03/2016 | 87,36 | 91,00 | 85,94 | 90,95 | +2,93% | 5,79% | 1.642.900 |
| 04/03/2016 | 89,91 | 90,19 | 87,92 | 88,36 | -1,22% | 2,52% | 1.703.400 |
| 03/03/2016 | 92,25 | 93,00 | 89,10 | 89,45 | -3,32% | 4,23% | 1.575.700 |
| 02/03/2016 | 88,94 | 93,42 | 88,75 | 92,52 | +3,29% | 5,25% | 2.779.100 |
| 01/03/2016 | 86,13 | 89,61 | 84,26 | 89,57 | +4,77% | 6,21% | 1.991.100 |
| 29/02/2016 | 86,83 | 88,97 | 84,60 | 85,49 | -1,74% | 5,03% | 1.757.500 |
| 26/02/2016 | 86,44 | 87,93 | 85,39 | 87,00 | +1,72% | 2,94% | 1.408.200 |
| 25/02/2016 | 87,33 | 88,94 | 84,34 | 85,53 | -1,43% | 5,27% | 1.387.800 |
| 24/02/2016 | 84,12 | 87,09 | 82,44 | 86,77 | +1,75% | 5,53% | 1.809.400 |
| 23/02/2016 | 88,06 | 89,30 | 84,76 | 85,28 | -4,18% | 5,16% | 1.757.700 |
| 22/02/2016 | 89,41 | 91,60 | 87,85 | 89,00 | +1,04% | 4,19% | 1.599.900 |
| 19/02/2016 | 85,99 | 88,51 | 84,04 | 88,08 | +1,66% | 5,20% | 2.029.700 |
| 18/02/2016 | 87,87 | 88,47 | 85,76 | 86,64 | -1,82% | 3,08% | 2.133.900 |
| 17/02/2016 | 86,07 | 88,46 | 83,50 | 88,25 | +3,37% | 5,76% | 2.276.300 |
| 16/02/2016 | 85,42 | 85,85 | 83,01 | 85,37 | +2,57% | 3,32% | 2.191.100 |
| 12/02/2016 | 81,94 | 83,81 | 79,50 | 83,23 | +4,42% | 5,26% | 2.771.700 |
| 11/02/2016 | 79,21 | 81,17 | 78,51 | 79,71 | -2,47% | 3,36% | 3.894.600 |
| 10/02/2016 | 82,26 | 84,06 | 80,25 | 81,73 | +1,98% | 4,63% | 4.115.300 |